In the absence of cGAS or when its function is impaired, the efficacy of immune checkpoint inhibition therapy is significantly diminished, suggesting that the presence of cGAS is a crucial factor in the success of tumor immunotherapy [86]. The gene discussed is CGAS; the disease is neoplasm.